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                                     INTRODUCTION 
Post burn itching is one of the common problem faced by burn victims. Burn 
injuries can lead to severe and persistent itching as the wounds heal. The itching 
may not necessarily stop when the wound is completely healed but may continue 
for many months.  About 87% of discharged adults with burn injury complain of 
itching.  Most children who have suffered a burn usually experience itching at 
some point during the healing process. Not only does it cause distress to both 
child and parent, but also the frequent excoriation may damage skin graft and 
necessitate further surgery.1 
The extent of burns is not a valid indicator of the degree of post-burn itch. As 
regards to the depth, the longer the healing time or re-epithelialization time, the 
higher the risk of significant itching.  Burns healing in less than 10 days rarely 
itch. Burns requiring over three weeks to heal usually have some degree of 
itching. Grafted burns are insensate for months and do not itch. 
The degree of wound erythema and early scarring are good markers, but the 
itching usually precedes the peak scar formation. There is considerable variability 
in the degree of tissue reaction to any burn depth. Treatment for pruritus is 
initiated when itching begins, as there are no preventative measures, with the 
exception of skin moisturizers, to decrease dryness. Pressure garments are used 
to decrease the wound blood flow, but the value of pressure garments in 
controlling itching is variable. 
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Currently the standard measures of controlling itching using antihistamines, pain 
medication, skin moisturizers, and pressure are effective in less than 20 percent 
of burn patients who have severe itch. Although the exact mechanism of post-
burn itching is unclear, it is clear that histamine plays a major role as is the case 
in other forms of dermatitis-induced itch. Increased histamine release in the 
healed burn wound is well documented as is the increased number of wound 
mast cell histamine release. In addition, a host of other inflammatory mediators 
are present in an inflammatory wound, such as kinins and substance P, which 
increase histamine release and also can potentiate the pruritogenic effects of 
histamine.1 
Anticonvulsant drugs have been used for a considerable time in the management 
of neuropathic  pain . The pathway for itch, like the pathway for pain , invoves the 
spinothalamic tracts and C fibres. Because of the similarity between itch and pain 









AIMS AND OBJECTIVIES 
The aims and objectives of the study are: 
To evaluate the effect of oral Gabapentin in the relief of itching due to wound 
healing and hypertrophic scars in burns patients. 













MATERIALS AND METHODS 
This was a one year prospective   study of role of Gabapentin in the treatment of 
itching causing by wound healing in the post burn hypertrophic scars in the 
Department of Plastic surgery, Christian Medical College, Vellore.  The 
prospective study was conducted from July 1st 2008 to June 30th, 2009.  The 
relief of itching is evaluated after administration of Gabapentin.  The study group 
selected comprises of the patients who has sustained thermal, electrical, and 
chemical burns / healed burns atleast 4 weeks after the burn event to 2 years 
after the burn event were included. The dose of Gabapentin to be used is 100mg 
three times daily in adults and increased to the maximum 0f 300mg three times 
daily depending on the response and 5-10 mg per kilogram body weight in 
children.  Patients are assessed once in every 7 days in person or through phone 
for a period of 3 months and once in 15 days for next 3 months after 
administration of Gabapentin for the relief of itching. Treatment success is 
determined by relief or reduction of itching after administration of above 




                                  
 5 
Inclusion Criteria: 
 Male and Female Patients between 5  years and 60 years of age. 
Patients with thermal, chemical and electrical burns between 4weeks to 2 
years after complete healing. 
Exclusion Criteria: 
 Male and Female Patients below 5 years and above 60 years of age. 
Male and Female patients within 4 weeks of burn incident or after  2 years 
after the burn incident. 
 Patients who are already on other medications which can cause sedation. 
 Female patients with confirmed pregnancy or history of amenorrohea. 
 Lactating mothers who are actively breast feeding. 
 Itching caused by Keloids, or other dermatological conditions not related to 
burns. 
 Patients with post burn scars on other modalities of treatment such as     
Silicon gel sheet or  kenacort injection for the relief of itching. 
 Burn patients who had psychological and behavioral problems before the 
course of treatment. 
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Patient Demographics:  
The study comprised of 23 patients of burns with hypertrophic scars due to 
thermal, electrical and scald burns.  Almost all the patients gave history of 
delayed healing of wounds [more than 3 weeks].   
Out of 23 patients, 18 [78.2%] had sustained thermal burns, 3 [13.04%] sustained 
electrical burns with flash injuries, and 2 [8.6%] had sustained scald burns. 
Out of 23 patients, 10 patients were adult males, 9 were females, and 4 were 
children. 
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Methods 
 The following statistical method has been applied. 
Preliminary analysis was done for demographic variables like sex and Age. 
Frequencies of the above variables have been output and corresponding Pie 
charts has been produced. 
Descriptive statistics like Mean, Median, Mode and Range, Minimum, Maximum 
has been produced for continuous variables like Pre GABA scores and Post 
GABA scores at different months. 
Then the Hypothesis that change in GABA score over time (in months) with Pre 
GABA scores was tested using Repeated Measures ANOVA Technique. 
Individual Comparisons has been done to see whether Pair wise (baseline with 
other  
time points) were tested with Bonferroni Correction. 






Measurement of itching 
The Itch Severity Scale9 
1. The itching from your post burn ulcers / hypertrophic scars : 
 a. Occasional [1] 
 b. Often [2] 
 c. Always [3] 
2. The severity of itching from your post burn ulcers / hypertrophic scars: 
a. To a small extent [1] 
 b. To a moderate extent [2] 
 c. To a great extent [3] 
3. Disturbance of night sleep due to itching is: 
a. To a small extent [1] 
 b. To a moderate extent [2] 
 c. To a great extent [3] 
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4. Change of mood due to itching is: 
    a. To a small extent [1] 
    b. To a moderate extent [2} 
    c. To a great extent [3] 
5. Disturbence in work and physical activity due to itching is: 
  a. To a small extent [1] 
  b. To a moderate extent [2] 
  c. To a great extent [3] 
6. Does it affect your concentration and studies? 
  a. To a small extent [1] 
  b. To a moderate extent [2] 
  c. To a great extent [3] 
7. Disturbance of sexual function: 
    a. To a small extent [1] 
     b. To a moderate extent [2] 
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     c. To a great extent [3] 
8. You are suffering form itching since how many months? 
  a. 3 months  
  b. 6 months. 
  c. 1 year. 
  d. 2 years 
9. What percentage of your itching has improved after starting Gabapentin 
tablets? 
  a.25%  
  b.50% 
  c.75% 
  d. > 75%        





10. Please shade in the areas where you tend to be itchy 
 
The results were considered as: 
Good:  7-10 points. 
Fair: 10-12 points. 
 Poor: >13 points. 
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REVIEW OF LITERATURE 
ANATOMY OF SKIN 
 
Diagram of Skin Layers 
The skin is an ever-changing organ that contains many specialized cells and 
structures. The skin functions as a protective barrier that interfaces with a 
sometimes-hostile environment. It is also very involved in maintaining the proper 
temperature for the body to function well. It gathers sensory information from the 
environment, and plays an active role in the immune system protecting us from 
disease. Understanding how the skin can function in these many ways starts with 
understanding the structure of the 3 layers of skin - the epidermis, dermis, and 
subcutaneous tissue.  
 13 
Epidermis 
The epidermis is the outer layer of skin. The thickness of the epidermis varies in 
different types of skin. It is the thinnest on the eyelids at .05 mm and the thickest 
on the palms and soles at 1.5 mm.  
The epidermis contains 5 layers. From bottom to top the layers are named:  
Stratum basale  
Stratum spinosum  
Stratum granulosum  
Stratum lucidum  
Stratum corneum 
The bottom layer, the stratum basale, has cells that are shaped like columns. In 
this layer the cells divide and push already formed cells into higher layers. As the 
cells move into the higher layers, they flatten and eventually die.  
The top layer of the epidermis, the stratum corneum, is made of dead, flat skin 
cells that shed about every 2 weeks.  
Specialized Epidermal Cells 
There are three types of specialized cells in the epidermis.  
The melanocyte produces pigment (melanin)  
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The Langerhan's cell is the frontline defense of the immune system in the skin2  
Dermis 
The dermis also varies in thickness depending on the location of the skin. It is .3 
mm on the eyelid and 3.0 mm on the back. The dermis is composed of three 
types of tissue that are present throughout - not in layers. The types of tissue are:  
Collagen  
Elastic tissue  
Reticular fibers 
Layers of the Dermis 
The two layers of the dermis are the papillary and reticular layers.  
The upper, papillary layer contains a thin arrangement of collagen fibers.  
The lower, reticular layer is thicker and made of thick collagen fibers that are 
arranged parallel to the surface of the skin. 
Specialized Dermal Cells 
The dermis contains many specialized cells and structures.  
The hair follicles are situated here with the erector pili muscle that attaches to 
each follicle.2  
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Sebaceous (oil) glands and apocrine (scent) glands are associated with the 
follicle.  
This layer also contains eccrine (sweat) glands, but they are not associated with 
hair follicles.  
Blood vessels and nerves course through this layer. The nerves transmit 
sensations of pain, itch, and temperature.  
There are also specialized nerve cells called Meissner's and Vater-Pacini 
corpuscles that transmit the sensations of touch and pressure. 
Subcutaneous Tissue 
The subcutaneous tissue is a layer of fat and connective tissue that houses larger 
blood vessels and nerves. This layer is important is the regulation of temperature 
of the skin itself and the body. The size of this layer varies throughout the body 
and from person to person.  
Epidermal Appendages 
Epidermal appendages are intradermal epithelial structures lined with epithelial 
cells with the potential for division and differentiation. These are important as a 
source of epithelial cells, which accomplish re-epithelialization should the 
overlying epidermis be removed or destroyed in situations such as partial 
thickness burns, abrasions, or split-thickness skin graft harvesting. Epidermal 
appendages include sebaceous glands, sweat glands, apocrine glands, 
mammary glands, and hair follicles. They often are found deep within the dermis, 
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and in the face may even lie in the subcutaneous fat beneath the dermis. This 
accounts for the remarkable ability of the face to re-epithelialize even the deepest 
cutaneous wounds.  
Sebaceous glands.2 
Sebaceous glands, or holocrine glands, are found over the entire surface of the 
body except the palms, soles, and dorsum of the feet. They are largest and most 
concentrated in the face and scalp where they are the sites of origin of acne. The 
normal function of sebaceous glands is to produce and secrete sebum, a group 
of complex oils including triglycerides and fatty acid breakdown products, wax 
esters, squalene, cholesterol esters, and cholesterol. Sebum lubricates the skin 
to protect against friction and makes it more impervious to moisture. 
Sweat glands  
Sweat glands, or eccrine glands, are found over the entire surface of the body 
except the vermillion border of the lips, external ear canal, the nail beds, labia 
minora, the glans penis, and the inner aspect of the prepuce. They are most 
concentrated in the palms and soles and the axillae. Each gland consists of a 
coiled secretory intradermal portion that connects to the epidermis via a relatively 
straight distal duct. The normal function of the sweat gland is to produce sweat, 
which cools the body by evaporation. The thermoregulatory center in the 
hypothalamus controls sweat gland activity through sympathetic nerve fibers that 
innervate the sweat glands. Sweat excretion is triggered when core body 
temperature reaches or exceeds a set point. 
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Apocrine glands 
Apocrine glands are similar in structure but not identical to eccrine glands. They 
are found in the axillae, in the anogenital region, and, as modified glands, in the 
external ear canal (ceruminous glands), in the eyelid (Moll's glands), and in the 
breast (mammary glands). 
Hair follicles 
Hair follicles are complex structures formed by the epidermis and dermis. They 
are found over the entire surface of the body except the soles of the feet, palms, 
glans penis, clitoris, labia minora, mucocutaneous junction, and portions of the 
fingers and toes. Sebaceous glands often open into the hair follicle rather than 
directly onto the skin surface, and the entire complex is termed the pilosebaceous 
unit. 
Blood Supply of the Skin 
Cutaneous vessels ultimately arise from underlying named source vessels. Each 
source vessel supplies a 3-dimensional vascular territory from bone to skin 
termed an angiosome. Adjacent angiosomes have vascular connections via 
reduced caliber (choke) vessels or similar caliber (true) anastomotic vessels. The 
cutaneous vessels originate either directly from the source arteries 
(septocutaneous or fasciocutaneous perforators) or as terminal branches of 
muscular vessels (musculocutaneous perforators).  
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During their course to the skin, they travel within or adjacent to the connective 
tissue framework and supply branches to each tissue with which they come into 
close contact (bone, muscle, fascia, nerve, fat). They emerge from the deep 
fascia in the vicinity of the intermuscular or intramuscular septa or near tendons 
and travel toward the skin, where they form extensive subdermal and dermal 
plexuses. The dermis contains horizontally arranged superficial and deep 
plexuses, which are interconnected via communicating vessels oriented 
perpendicular to the skin surface. Cutaneous vessels ultimately anastomose with 
other cutaneous vessels to form a continuous vascular network within the skin.  
In addition to the skin's natural heat conductivity and loss of heat from the 
evaporation of sweat, convection from cutaneous vessels is a vital component of 
thermoregulation. Cutaneous blood flow is 10-20 times that required for essential 
oxygenation and metabolism, and large amounts of heat can be exchanged 
through the regulation of cutaneous blood flow. The thermoregulatory center in 
the hypothalamus controls vasoconstriction and vasodilatation of cutaneous 
vessels through the sympathetic nervous system.2 
Lymphatics 
Skin lymphatics parallel the blood supply and function to conserve plasma 
proteins and scavenge foreign material, antigenic substances, and bacteria. 
Blind-ended lymphatic capillaries arise within the interstitial spaces of the dermal 
papillae. These unvalved superficial dermal vessels drain into valved deep 
dermal and subdermal plexuses. These then coalesce to form larger lymphatic 
channels, which course through numerous filtering lymph nodes on their way to 
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join the venous circulation near the subclavian vein-internal jugular vein junction 
bilaterally.2 
Skin Innervation 
Sensory perception is critically important in the avoidance of pressure, 
mechanical or traumatic forces, and extremes of temperature. Numerous 
specialized structures are present in the skin to detect various stimuli. As 
previously mentioned, Merkel cells of the epidermis detect light touch. Meissner 
corpuscles also detect light touch. These are found in the dermal papillae and are 
most concentrated in the fingertips. Pacini corpuscles are found deep within the 
dermis or even in the subcutaneous tissue. These structures are specialized to 
detect pressure.  
Pain is transmitted through naked nerve endings located in the basal layer of the 
epidermis. Krause bulbs detect cold, whereas Raffini corpuscles detect heat. 
Heat, cold, and proprioception also are located in the superficial dermis. 
Cutaneous nerves follow the route of blood vessels to the skin. The area supplied 
by a single spinal nerve, or single segment of the spinal cord, is termed a 
dermatome. Adjacent dermatomes may overlap considerably, of importance to 






Wound healing, or wound repair, is an intricate process in which the skin  repairs 
itself after injury. In normal skin, the epidermis and dermis exists in a steady-
stated equilibrium, forming a protective barrier against the external environment. 
Once the protective barrier is broken, the physiologic process of wound healing is 
immediately set in motion. The classic model of wound healing is divided into 
three or four sequential, yet overlapping, phases: (1) hemostasis (not considered 
a phase by some authors), (2) inflammatory, (3) proliferative and (4) remodeling. 
The proliferative phase. 
The proliferative phase is characterized by angiogenesis, collagen deposition, 
granulation tissue formation, epithelialization, and wound contraction. In 
angiogenesis, new blood vessels are formed by vascular endothelial cells. In 
fibroplasia and granulation tissue formation, fibroblasts grow and form a new, 
provisional extracellular matrix (ECM) by excreting collagen and fibronectin. 
Concurrently, re-epithelialization of the epidermis occurs, in which epithelial cells 
proliferate and 'crawl' atop the wound bed, providing cover for the new tissue.  
In contraction, the wound is made smaller by the action of myofibroblasts, which 
establish a grip on the wound edges and contract themselves using a mechanism 
similar to that in smooth muscle cells. When the cells' roles are close to complete, 
unneeded cells undergo apoptosis.  
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In the maturation and remodeling phase, collagen is remodeled and realigned 
along tension lines and cells that are no longer needed are removed by 
apoptosis. 
However, this process is not only complex but fragile, and susceptible to 
interruption or failure leading to the formation of chronic non-healing wounds. 
Factors which may contribute to this include diabetes, venous or arterial disease, 
old age, and infection.  
Inflammatory phase 
In the inflammatory phase (lag phase/resting phase), clotting takes place in order 
to obtain hemostasis, or stop blood loss, and various factors are released to 
attract cells that phagocytise debris, bacteria, and damaged tissue and release 
factors that initiate the proliferative phase of wound healing. 
Clotting cascade 
Coagulation 
When tissue is first wounded, blood comes in contact with collagen triggering 
blood platelets to begin secreting inflammatory factors. Platelets also express 
glycoproteins on their cell membranes that allow them to stick to one another and 
to aggregate forming a mass. 
Fibrin and fibronectin cross-link together and form a plug that traps proteins and 
particles and prevents further blood loss. This fibrin-fibronectin plug is also the 
main structural support for the wound until collagen is deposited. Migratory cells 
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use this plug as a matrix to crawl across, and platelets adhere to it and secrete 
factors. The clot is eventually lysed and replaced with granulation tissue and then 
later with collagen. 
Platelets 
Platelets, the cells present in the highest numbers shortly after a wound occurs, 
release a number of things into the blood, including ECM proteins and cytokines, 
including growth factors. Growth factors stimulate cells to speed their rate of 
division. Platelets also release other proinflammatory factors like serotonin, 
bradykinin, prostaglandins, prostacyclins, thromboxane, and histamine, which 
serve a number of purposes, including to increase cell proliferation and migration 
to the area and to cause blood vessels to become dilated and porous.. 
Vasoconstriction and vasodilatation 
Immediately after a blood vessel is breached, ruptured cell membranes release 
inflammatory factors like prostaglandins and thromboxanes that cause the vessel 
to spasm to prevent blood loss and to collect inflammatory cells and factors in the 
area. This vasoconstriction lasts five to ten minutes and is followed by 
vasodilation, a widening of blood vessels, which peaks at about 20 minutes post-
wounding. Vasodilation is the result of factors released by platelets and other 
cells. The main factor involved in causing vasodilation is histamine. Histamine 
also causes blood vessels to become porous, allowing the tissue to become 
edematous because proteins from the bloodstream leak into the extravascular 
space, which increases its osmolar load and draws water into the area. Increased 
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porosity of blood vessels also facilitates the entry of inflammatory cells like 
leukocytes into the wound site from the bloodstream.  
Polymorphonuclear neutrophils 
Within an hour of wounding, polymorphonuclear neutrophils (PMNs) arrive at the 
wound site and become the predominant cells in the wound for the first two days 
after the injury occurs, with especially high numbers on the second day. They are 
attracted to the site by fibronectin, growth factors, and substances such as kinins. 
Neutrophils phagocytise debris and bacteria and also kill bacteria by releasing 
free radicals in what is called a 'respiratory burst'. They also cleanse the wound 
by secreting proteases that break down damaged tissue. Neutrophils usually 
undergo apoptosis once they have completed their tasks and are engulfed and 
degraded by macrophages.  
Other leukocytes to enter the area include helper T cells, which secrete cytokines 
to cause more T cells to divide and to increase inflammation and enhance 
vasodilation and vessel permeability. T cells also increase the activity of 
macrophages.  
Macrophages 
Macrophages are essential to wound healing. They replace PMNs as the 
predominant cells in the wound by two days after injury. Attracted to the wound 
site by growth factors released by platelets and other cells, monocytes from the 
bloodstream enter the area through blood vessel walls. Numbers of monocytes in 
the wound peak one to one and a half days after the injury occurs. Once they are 
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in the wound site, monocytes mature into macrophages. Recently it has been 
found that the spleen contains half the body's monocytes in reserve ready to 
deployed to injured tissue.  
The macrophage's main role is to phagocytise bacteria and damaged tissue, and 
it also debrides damaged tissue by releasing proteases. Macrophages also 
secrete a number of factors such as growth factors and other cytokines, 
especially during the third and fourth post-wounding days. These factors attract 
cells involved in the proliferation stage of healing to the area. Macrophages are 
stimulated by the low oxygen content of their surroundings to produce factors that 
induce and speed angiogenesis.] And they also stimulate cells that reepithelialize 
the wound, create granulation tissue, and lay down a new extracellular matrix.By 
secreting these factors, macrophages contributes in pushing the wound healing 
process into the next phase. 
Decline of inflammatory phase 
As inflammation dies down, fewer inflammatory factors are secreted, existing 
ones are broken down, and numbers of neutrophils and macrophages are 
reduced at the wound site.  These changes indicate that the inflammatory phase 
is ending and the proliferative phase is underway.  
Because inflammation plays roles in fighting infection, clearing debris and 
inducing the proliferation phase, it is a necessary part of healing. However, 
inflammation can lead to tissue damage if it lasts too long. Thus the reduction of 
inflammation is frequently a goal in therapeutic settings. Inflammation lasts as 
long as there is debris in the wound.  
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Proliferative phase 
About two or three days after the wound occurs, fibroblasts begin to enter the 
wound site, marking the onset of the proliferative phase even before the 
inflammatory phase has ended. As in the other phases of wound healing, steps in 
the proliferative phase do not occur in a series but rather partially overlap in time. 
The proliferative phase is also called the reconstruction phase. 
Angiogenesis 
Also called neovascularization, the process of angiogenesis occurs concurrently 
with fibroblast proliferation when endothelial cells migrate to the area of the 
wound. Because the activity of fibroblasts and epithelial cells requires oxygen 
and nutrients, angiogenesis is imperative for other stages in wound healing, like 
epidermal and fibroblast migration. The tissue in which angiogenesis has 
occurred is erythematous due to the presence of capillaries. 
Stem cells of endothelial cells, originating from parts of uninjured blood vessels, 
develop pseudopodia and push through the ECM into the wound site to establish 
new blood vessels. Endothelial cells are attracted to the wound area by 
fibronectin found on the fibrin scab and chemotactically by angiogenic factors 
released by other cells, e.g. from macrophages and platelets when in a low-
oxygen environment. Endothelial growth and proliferation is also directly 
stimulated by hypoxia, and presence of lactic acid in the wound.  
To migrate, endothelial cells need collagenases and plasminogen activator to 
degrade the clot and part of the ECM. Zinc-dependent metalloproteinases digest 
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basement membrane and ECM to allow cell migration, proliferation and 
angiogenesis. When macrophages and other growth factor-producing cells are no 
longer in a hypoxic, lactic acid-filled environment, they stop producing angiogenic 
factors. Thus, when tissue is adequately perfused, migration and proliferation of 
endothelial cells is reduced. Eventually blood vessels that are no longer needed 
die by apoptosis. 
 Fibroplasia and granulation tissue formation 
Simultaneously with angiogenesis, fibroblasts begin accumulating in the wound 
site. Fibroblasts begin entering the wound site two to five days after wounding as 
the inflammatory phase is ending, and their numbers peak at one to two weeks 
post-wounding. By the end of the first week, fibroblasts are the main cells in the 
wound Fibroplasia ends two to four weeks after wounding. 
In the first two or three days after injury, fibroblasts mainly proliferate and 
migrate, while later, they are the main cells that lay down the collagen matrix in 
the wound site. Fibroblasts from normal tissue migrate into the wound area from 
its margins. Initially fibroblasts use the fibrin scab formed in the inflammatory 
phase to migrate across, adhering to fibronectin. Fibroblasts then deposit ground 
substance into the wound bed, and later collagen, which they can adhere to for 
migration.  
Granulation tissue functions as rudimentary tissue, and begins to appear in the 
wound already during the inflammatory phase, two to five days post wounding, 
and continues growing until the wound bed is covered. Granulation tissue 
consists of new blood vessels, fibroblasts, inflammatory cells, endothelial cells, 
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myofibroblasts, and the components of a new, provisional extracellular matrix 
(ECM). The provisional ECM is different in composition from the ECM in normal 
tissue and its components originate from fibroblasts. Such components include 
fibronectin, collagen, glycosaminoglycans, and proteoglycans. Its main 
components are fibronectin and hyaluronin, which create a very hydrated matrix 
and facilitate cell migration Later this provisional matrix is replaced with an ECM 
that more closely resembles that found in non-injured tissue. 
Growth factors and fibronectin encourage proliferation, migration to the wound 
bed, and production of ECM molecules by fibroblasts. Fibroblasts also secrete 
growth factors that attract epithelial cells to the wound site.  
HYPERTROPHIC SCARS18 
Wound repair normally culminate in fine line scars, however the repair process 
may go awry and wounds may heal with large raised collagenous scars known as 
keloids or hypertrophic scars.Both lesions have the annoying clinical symptoms 
of itching, tenderness and pain.18 
Hyperopic scars are often raised and red, remain within the confines of the 
wound and tend to regress over a period of time .The complications of these 
abnormal scar formations are often severe and their clinical management is 
frustrating. 
Etiology: Keloids and hypertrophic scars are unique to man. Hypertrophic scars 
are fibroproliferative disorders of wound healing with excess healing. However 
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because there are no animal models there are few biochemical or molecular data 
that may indicate which factors may initiate hypertrophic scar formation. 
Diagnosis: Hypertrophic scars appear to be self limiting type of over healing 
following injury. With time the raised, red hypertrophic scar becomes pale and 
flat. If there is a doubt biopsy is mandatory. 
Treatment modalities: Several types of treatment modalities have been tried with 
varying degrees of success.  The surgeon should ascertain whether the patient’s 
objective is to eradicate the esthetic and /or functional deformity or to prevent 
recurrence by surgery or by pharmacological therapy or whether the objective is 
merely ameliorate physical discomfort and itching. 
Pharmacologic: directed towards either decreasing protein production or 
enhancing collagen turnover. Steroids affect the former and lathyrogens and 
penicillamine are agents used to accomplish the latter. Steroids like 
Triamcinolone  acetonide are best used in concentration of 40 mg per ml. 
Injections are usually given 6 to 8 weeks apart.  
Mechanical: Mechanical pressure has been known to inhibit hypertrophic scar 
production by altering glycosaminoglycan content and blood vessel permeability 
of healing wounds and thus subsequently curtailed scar formation by altering 
normal collagen –GAG interaction during wound healing. Also it has been 
suggested that mechanical pressure increases collagenase activity which in turn 
prevents excessive collagen deposition.. 
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Radiation: Radiation nonselectively destroys collagen producing fibroblasts in 
the lesions as well as surrounding connective tissue and cells. 
Surgery:Mechanical factors of surgical wound closure affecting scar appearance; 
Amount of scar tissue-Avoid use of large foreign body sutures,applying pressure 
and prevention of hematoma may decrease amount of scar. 
Lines of minimal tension-Lines parallel to muscle pull resolve earlier and and 
remain finer. 
Shape of scars-avoid semicircular scar as it may become puffy and raised(trap 
door scar) 
Skin suture marks-closure with subcuticular sutures takes the burden of tension 
from the skin sutures and allows their early removal thus avoiding most risks of 
suture marks. 
Location of scars-some areas of body ( eg eyelids,forehead ) heal with less 
noticeable scars than others.18 
Incidence and Characteristics of itching in burn patients22 
Itching in the healed burn patient is considered to be one of the most problematic 
and distressing issues that the patient experiences. Staff in any burn centre can 
attest to both the magnitude of the problem as well as the fact that no effective 
treatiment exists.22 
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The itch experienced by the burn survivor can be described by three criteria- 
incidence, severity, and duration. 
The incidence of significant itching in burn survivors is approximately 50% for 
adults and close to 100% for children. 
The severity has always been difficult to evaluate. However, studies using a 10 
point linear visual analog scale, have demonstrated that itch ranges from 5 to 7 in 
patients already on standard antihistamine therapy.22 
IMPACT OF ITCHINNG: 22 
>Impedes sleep  
> Impedes work and play. 
> Impedes therapy. 
> Impedes eating. 
> Creates depression and anxiety 
> Impairs quality of life 
THE INCIDENCE: 
Despite using oral antihistamines, "severe itching" is reported to be present in : 
*Approximately 70% of children.  
*Approximately 50% of adults. 
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The characteristics of itch are: 
-Starts during healing. 
 -most prominent with time of closure over 3 weeks. 
-worse for partial thickness burns. 
-Accentuated by healing, activity. 
-Worse at night. 
-Lasts months to years. 
Pathophysiology of itching:6 
ITCH AND PAIN: Itch is considered by many investigators to be a form of pain. 
The similarity is that itch shares with a peripheral group of C fibers, a group of 
dorsal horn interneurons and specific pathway in the anterolateral spinal cord to 
brain. Both itch and pain disappear when the pathway is cut. The C fibers carry 
both itch and pain stimuli. However, itch can only be produced, by superficial 
skin. Deep stimuli produce pain. Another similarity is that fact that histamine 
placed just beneath the epidermis leads to intense itching while histamine 
injected deeper in the skin produces pain. Another similarity is a strong itch 
stimulus to skin such as light touch, imitates the secondary hyperalgesia in which 
the surrounding painful focus is also painful to light touch. The mechanism is the 
spreading of hyperactivity of neurons in the cord following a C fiber volley. Pain 
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will override the itch sensation the itch sensation if a painful stimulation occurs in 
the area of the itch.6 
Likely both use the same skin C-fibers for the pathway to the brain. 
Itch is caused by stimulation of a restricted number of C fibers.13 
A small afferent volley signals itch. 
A larger activation of C fibers will cause pain. 
Itch is only present on the surface of skin. 
Pain can be present on the surface and deeper portion of skin 
Morphine causes itch but stops pain. 
HISTAMINE AND BURN ITCH: The most common hypothesis for the skin itch 
and in the healed wound is the stimulation of skin sensory nerve fibers by 
Histamine. The histamine produced in the skin and especially in the burn wound 
is by the increased number of mast cells. Secondly, Histamine applied in low 
concentrations to the epidermo-dermal junction causes intense itching. Third, 
histamine causes itch by binding to the H1 receptor, found in large concentrations 
in skin. 
The healed partial thickness burn wound or donor site appears to be most prone 
to itch due to injury induced alteration in the superficial nerve fibers making them 
more sensitive to histamine and secondly, The presence of increased number of 
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histamine factories, namely the mast cells. A number of other agents, known to 
induce itch, appear to act indirectly through stimulation of histamine release or 
potentiation of the itching effect of histamines. 
The mechanism of itching is not clearly defined, but increased histamine release 
from the wound is a likely etiological factor. The source of the histamine would be 
the increased mast cell population typically present in the chronically pruritic 
wound. Any wound manipulation or increase in wound temperature exacerbates 
the itching. 
The mechanism of itch is considered to be the activation of the wound surface C 
nerve fibers. The C fibers are typically considered to be pain fibers, and itch has 
been categorized as a form of pain. Histamine also increases surface wound 
blood flow, which would explain the raised red surface usually present on the 
chronically itching wound.22 
The current standard pharmacologic management of itch is the use of oral 
antihistamines with the frequent addition of sedatives. However, this approach is 
successful in less than half of the chronically itching burn patients.14 
Doxepin, a tricyclic compound used for clinical depression, has been found to 
have very potent H1 and H2 histamine receptor blocking properties. Doxepin, 
which is available as 5%  topical cream has been reported to be effective in 
controlling the itching and erythema of more acute pruritic burn wound up to three 
months from the time of healing. 
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Criteria for the use of Doxepin were: The burn wound must be healed. In addition, 
the pruritic wound could not exceed 20% of total body surfce, and the total initial 
burn could not exceed 35% of the body. Larger burn injuries usually have other 
causes of discomfort, which are hard to distinguish from itch. Doxepin could not 
used in acute post burn period or immedietly after debridment and skin grafting.4 
Many of the treatments available to reduce itching can be used when the wounds 
are healed, these include colloid and oatmeal baths, local anaesthetic creams 
and massage therapy. 5% doxepin cream can be used only after the wound 
healing is complete. Doxepin is not recommended for children under 12 years. 
Drowsiness can be significant with this cream. 
Antihistamines are the current mainstay of treatment. Vitale et al compared three 
different oral antihistamines and found that they provided complete relief of itch in 
only 20% of patients. Severe itching was still reported in more than 70% of 
patients. The side effect with the highest incidence and common to all 
antihistamines was sedation, and it may the sedation itself that relieves the 
itching. 
Ondensetron is a 5HT-3 receptor antagonist used for prevention of nausea and 
vomiting in patients receiving chemotherapy/ radiation therapy. Serotonin [5HT], 
a central and peripheral acting substance implicated in other pruritogenic 
processes such as uraemia  and cholestastis, could reasonably be implicated in 
the burn pruritis pathway as well. 
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Pain and itch are thought to be conducted via C-fibres that are influenced to a 
degree by serotonin. By inhibiting this influence at the 5HT3 receptor, pruritis may 
also be inhibited. 
The comparative trial has been done between ondensetron and antihistamines 
has been done. 17 patients had participated in the drug study. Pretreatment 
itching scores were similar for both drugs 6 for dyphenhydramine and 6.35 for 
ondensetron. Post treatment scores were 3.41 for dyphenhydramine and 2.65 for 
ondensetron. The greater benefit in the ondensetron group was not dramatically 
better than dyphenhydramine  . 
Anticonvulsant drugs have been used for a considerable time in the management 
of neuropathic pain .  
Pharmacology of Gabapentin8 
Gabapentin is an anti-seizure drug that consists of a GABA molecule covalently 
bound to a lipophilic cyclohexane ring. Gabapentin was designed to be a centrally 
active GABA agonist, with its high lipid solubility aimed at facilitating its transfer 
across the blood- brain barrier.8 
Pharmacological effects and mechanism of action 
Gabapentin inhibits tonic hindlimb extension in the electroshock seizure model. 
Gabapentin also inhibits clonic seizures induced by  pentylenetetrazol.  Its 
efficacy in both these tests parallels that of valproic acid and distinguishes it from 
phenytoin and carbamazepine. The anticonvulsant effect of Gabapentin is 
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unknown. Gabapentin may promote nonvesicular release of GABA  through a 
poorly understood mechanism. Gabapentin binds protein in cortical membranes 
with an amino acid sequence  identical to that of  the alpha2 delta subunit of the L 
type of voltage-sensitive  calcium channel.8 
Pharmacodynamics:    
Gabapentin is absorbed after oral administration and is not metabolized in 
humans.  It is not bound to plasma proteins. It is excreted unchanged, mainly in 
the urine. Its half-life, when used as a monotherpy, is is 4-6 hours. 
Therapeutic uses:   Gabapentin is effective for partial seizures, with or without 
secondary generalization, used in the treatment of neuropathic pain. 
Toxicity:  Overall, gabpentin is well tolerated with the most common adverse 
effects of somnolence, dizziness, ataxia, and fatigue. These effects usually are 
mild to moderate in severity but resolve within 2 weeks of onset during continued 
treatment.8 
Precautions and Contraindications: 
Patients who are allergic to gabapentin or other ingredients should not take 
gabapentin. 
Gabapentin should be use with caution in patients with neurological disorders 
and pregnant ladies. 
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Dose modification of gabapentin may be required in patients with renal failure or 
patients with compromised renal function. 
This drug may cause dizziness, caution should be taken before advising patients 
with involved in activities requiring alertness such as driving or using machinery 
Caution is advised when using this drug in the elderly because they may be more 
sensitive to its effects.  
Caution is advised when using this drug in children because they may be more 
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Results 
Statistical Methods Used: 
1. Variable Explanations: 
a. Age : Age of the Patients 
b. Pre : Pre GABA Score(Baseline) 
c. Post1 to Post7: Post GABA Scores(in Months) 
2. Hypothesis Tested : 
a. Is there any change over time (Months) in Mean GABA scores from 
baseline? Refer to :  Table 2 
b. If you wish to see at which time point (months) say whether there is 
any change over time in Mean GABA scores at Post1 and Post2? 
Refer to: Table 3 
3. Statistical Methods Applied: 
a. Repeated Measures ANOVA 
Descriptive Statistics 
 N Minimum Maximum Mean Std. Deviation 
age 20 5 45 25.70 10.717 
Pre 20 12 15 13.35 .875 
post1 20 7.25 10.00 8.3625 .60413 
post2 20 7.25 9.00 8.1000 .61985 
post3 20 7.25 8.75 8.0000 .52566 
post4 20 7.0 9.0 7.875 .5821 
post5 20 7.0 9.0 8.000 .6689 
post6 20 7.0 9.0 7.825 .7304 





Effect Value F 
Hypothesis 
df 
Error df Sig. 
score Pillai's Trace .964 62.438a 6.000 14.000 .000 
      
      
Interpretation:     
             It answers the first hypothesis, we conclude from the above table that there is 




Pairwise Comparisons  
 
 







Std. Error Sig.a 
95% Confidence Interval for 
Differencea 
Lower Bound Upper Bound 
1 
2 4.988* .288 .000 3.978 5.997 
3 5.250* .302 .000 4.191 6.309 
4 5.350* .282 .000 4.361 6.339 
5 5.475* .282 .000 4.487 6.463 
6 5.350* .321 .000 4.227 6.473 
7 5.525* .325 .000 4.385 6.665 
2 
1 -4.988* .288 .000 -5.997 -3.978 
3 .263 .105 .455 -.105 .630 
4 .363* .093 .021 .036 .689 
5 .488* .090 .001 .173 .802 
6 .363 .120 .144 -.056 .781 
7 .538* .148 .037 .020 1.055 
3 
1 -5.250* .302 .000 -6.309 -4.191 
2 -.263 .105 .455 -.630 .105 
4 .100 .088 1.000 -.207 .407 
5 .225 .081 .250 -.058 .508 
6 .100 .097 1.000 -.239 .439 
7 .275 .081 .063 -.008 .558 
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4 
1 -5.350* .282 .000 -6.339 -4.361 
2 -.363* .093 .021 -.689 -.036 
3 -.100 .088 1.000 -.407 .207 
5 .125 .092 1.000 -.196 .446 
6 .000 .089 1.000 -.311 .311 
7 .175 .110 1.000 -.212 .562 
5 
1 -5.475* .282 .000 -6.463 -4.487 
2 -.488* .090 .001 -.802 -.173 
3 -.225 .081 .250 -.508 .058 
4 -.125 .092 1.000 -.446 .196 
6 -.125 .125 1.000 -.563 .313 
7 .050 .102 1.000 -.307 .407 
6 
1 -5.350* .321 .000 -6.473 -4.227 
2 -.363 .120 .144 -.781 .056 
3 -.100 .097 1.000 -.439 .239 
4 .000 .089 1.000 -.311 .311 
5 .125 .125 1.000 -.313 .563 
7 .175 .122 1.000 -.252 .602 
7 
1 -5.525* .325 .000 -6.665 -4.385 
2 -.538* .148 .037 -1.055 -.020 
3 -.275 .081 .063 -.558 .008 
4 -.175 .110 1.000 -.562 .212 
5 -.050 .102 1.000 -.407 .307 
6 -.175 .122 1.000 -.602 .252 
Based on estimated marginal means    
*. The mean difference is significant at the .05 level.   

























Mean Median Mode 
Std. 
























20 0 7.8250 7.7500 7.00 .73045 2.00 7.00 9.00 
a. Multiple modes exist. The 
smallest value is shown 
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 < = 10 years 3 15.0 15.0 15.0 
11 - 20 Years 2 10.0 10.0 25.0 
21 - 30 Years 10 50.0 50.0 75.0 
> = 31 Years 5 25.0 25.0 100.0 

















Valid F 9 45.0 45.0 45.0 
M 11 55.0 55.0 100.0 









Post burn itching is one of the common problems associated with hypertrophic 
scars. It causes many problems to the patient, continuous discomfort, lack of 
concentration in study and work, disturbance in sleep, difficulty in postoperative 
period and over all quality of life. Post burn itching should be properly 
investigated and treated instead of prescribing antihistaminic drugs or other 
placebo drugs. 
The way in which itch is processed in the central nervous system is incompletely 
understood. Injection of histamine into the superficial layers of the skin stimulates 
itching in a dose dependent manner and it undoubtedly plays a role as increased 
histamine release in the healed burn wound is well documented. Prostaglandins 
lower the threshold for histamine to produce itching , and opioids, 5HT, 
substance P and many other neuropeptides may all be responsible for producing 
the itch sensation  and . 
Bickford  in 1938 hypothesized that itchy skin is mediated by a peripheral 
neurogenic mechanism. The pathway for itch, like the pathway for pain, involves 
the spinothalamic tracts and C fibres. Both itch and pain disappear when this 
pathway is cut. Pain and itch, however, are dissociable – opiate administration 
relieves pain but causes itch. Itch can be inhibited by noxious stimuli, thus they 
are distinct sensations that interact. Since pain and itch have similar pathways 
and similar sensitization of neurons they may have similar chemical transmission 
and hence respond to the same treatment. Central inhibitory neurons must also 
play a part in the perception of itch . 
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The neural basis for itching is still unclear but itching most likely has a multitude 
of mechanisms that may depend on the primary cause. 
Several reports show gabapentin can be used safely in children for treatment of 
epilepsy and neuropathic pain with minimal side effects. It seems now that it may 
also provide an alternative treatment to antihistamines for itching. The treatment 
has been so successful that it has now become standard treatment in our 
hospital. The drug should probably be used with care, if at all in children with 
behavioural difficulties as behaviour may deteriorate rapidly during treatment.6 
At follow up, the patients have stopped taking the drug as soon as the itching has 
stopped. For some, this is about 4 months; others have been taking it for up to 12 
months, especially if their wounds are hypertrophied. 
We have shown that gabapentin is an effective treatment for post-burn pruritis. 
We hope that larger burns centers will be able to research further into this 
promising new therapy. 
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SUMMARY 
The study comprised of 23 patients of burns with hypertrophic scars due to 
thermal, electrical and scald burns.  Almost all the patients gave history of 
delayed healing of wounds [more than 3 weeks].   
Out of 23 patients, 18 [78.2%] had sustained thermal burns, 3 [13.04%] sustained 
electrical burns with flash injuries, and 2 [8.6%] had sustained scald burns. 
Out of 23 patients, 10 patients were adult males, 9 were females, and 4 were 
children. 
We took detailed history of all these patients regarding the nature of burns, the 
type of treatment they received, time taken for burns to heal.  Medical history of 
neurological and behavioral disorders, history of renal dysfunction, pregnancy 
was ruled out before stating the Gabapentin therapy. Any hypersensitivity to 
Gabapentin or other anticonvulsants was ruled out. 
All the patients were thoroughly explained about the Gabapentin, its actions, side 
effects and precautions. Any doubt of the patient regarding the drug was properly 
clarified. The information and consent sheet was given to patient or the patient’s 
parents if the patient was a minor. After the patients read and understood, the 
consent sheet was signed by them and they were enrolled in to the drug trial. 
Most of the patients chosen were local patients  who can come for regular follow 
up and dose adjustment, for patients who are from far away places, advise was 
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given to stay in the city for at least one week for assessing the side effects and 
dose adjustment. 
Most of the patients were started with 100 mg of Gabapentin twice daily and 
gradually increased to 200 -300 mg thrice daily depending on the  improvement 
of relief from itching and tolerance to the drug. Most of the patients had minimal 
side effects like headache, dizziness, and nausea most of which subsided with 
continuation of treatment, dose adjustment or addition of symptomatic drugs like 
paracetamol, and domperidone.  
No patients experienced any serious side effects after starting Gabapentin. All 
the patients were advised to come back after a week for dose adjustments.  
A itch score questionnaire was given to them before starting the therapy and 
same questions were asked at weekly interval for 3 months and once in fortnight 
for another 6 months through telephone. Patients were called to O.P.D only in 
case of problems. All the scores were tabulated in a file and assessed about their 
improvement.  
More 80% of patients showed fairly good relief from itching within one month of 
starting the treatment and continued the treatment for 6 months to 1 year 
depending upon the severity of their burns.  All patients were relieved form 
discomfort of itching, were able to concentrate in work and school. House wives 
could do work better at home. Patients could sleep well without itching in the 
night times. Overall the quality of life was improved considerably. 
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Only 3 patients showed moderate or little improvement from gabapentin. They 
had long history of burns and extensive area of burns. 
 Exact reason why these patients were not relieved from itching was not known. 
These 2 patients were lost for long term follow up.  
Especially children showed remarkable improvement from itching after starting 
gabapentin. They showed improved performance in studies and extra-curricular 
activities. We have started gabapentin as a protocol for most of the patients with 








                           
 51 
CONCLUSIONS 
1. Gabapentin effectively combats post burn itching in patients with 
hypertrophic scars. 
2. Gabapentin showed improvement in work & play, improvement in quality 
of sleep. 
3. Gabapentin showed marked co-operation of patients to therapy during 
post operative period. 
4. It reduced depression and anxiety in post burn patients with itching. 
5. Gabapentin brought about an overall improvement in the quality of life in 
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Christian Medical College, Vellore 
Department of Plastic Surgery 
 
Study of role of  Gabapentin in post burn  itching. 
Information sheet 
You are being requested to participate in a study to see if a drug called 
Gabapentin can help you with post burn itching . We hope to include about 40 
people from this hospital in this study. 
 
What type of drug is Gabapentin? 
Gabapentin is an anti epileptic drug used in the treatment of seizures. It has been 
shown to reduce itching after burns. 
 
Does Gabapentin   have any side effects? 
 The side effects are minimal as you will be taking low dose of Gabapentin. 
However, side effects are nausea, vomiting, fatigue, headache, hyperkinesis, 
emotional lability, and behavioral problems. 
 
If you take part what will you have to do? 
If you agree to participate in this study, you will be given the tablet Gabapentin, to 
be taken three times a day.   
All other treatments that you are already on will be continued and your regular 
treatment will not be changed during this study. You will be expected to come for 
a review to the hospital 2 weeks after starting the tablet and again after 4 more 
weeks and finally after a further 4 weeks. Before starting the study and at each 
visit you will be asked questions about your sleep. No additional procedures or 
blood tests will be conducted routinely for this study.  
If at any time you experience any problems, you will be expected to report this to 
the doctor. You will also be contacted by telephone at least once in between the 
monthly visits by the doctors in this study who will ask you about any side effects 
you are experiencing. 
  
Can you withdraw from this study after it starts? 
Your participation in this study is entirely voluntary and you are also free to 
decide to withdraw permission to participate in this study. If you do so, this will 
not affect your usual treatment at this hospital in any way. In addition, if you 
experience any serious side effects or your condition worsens, the study tablets 
will be stopped and you may be given additional treatment.  
 
 
What will happen if you develop any study related injury? 
We do not expect any injury to happen to you but if you do develop any side 
effects or problems due to the study, these will be treated at no cost to you. We 




Will you have to pay for the study tablets?  
Yes. You need to buy these tablets.   The cost of tablets per day will be around 
10 rupees. 
 
How long I should take these tablets? 
You are expected to take tab. Gabapentin for 2 months. 
 
What happens after the study is over? 
You may or may not benefit from the study drug that you are given. Once the 
study is over, If Gabapentin has helped you and you wish to continue, then your 
doctor may prescribe it for you.   
 
Will your personal details be kept confidential? 
The results of this study will be published in a medical journal but you will not be 
identified by name in any publication or presentation of results. However, your 
medical notes may be reviewed by people associated with the study, without your 
additional permission, should you decide to participate in this study.  
 
1. If you have any further questions, please ask: Dr. Aravind Lakshmanarao 
Department of Plastic Surgery, CMC, Vellore. Ph.04164212017. email id : 
aravindlakshmanaro@gmail.com  or: Dr. M. Kingsly Paul, Associate Professor, 
Department of Plastic Surgery, CMC, Vellore. . Ph.04164212017. 
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CONSENT TO TAKE PART IN A CLINICAL TRIAL 
 
Study Title: Role of Gabapentin for the treatment of itching produced by 
acute burns and hypertrophic scars. 
 
Study Number: 
Participant’s name:  
Date of Birth / Age (in years): 
 
I_____________________________________________________________ 
___________, son/daughter of  ___________________________________ 
 
(Please tick boxes) 
Declare that I have read the information sheet provide to me regarding this study 
and have clarified any doubts that I had. [ ] 
I also understand that my participation in this study is entirely voluntary and that I 
am free to withdraw permission to continue to participate at any time without 
affecting my usual treatment or my legal rights [ ]  
I am aware that I have to take the tablet called Gabapentin for the period of three 
months. 
I understand that I will receive free treatment for any study related injury or 
adverse event but I will not receive and other financial compensation [ ] 
I understand that the study staff and institutional ethics committee members will 
not need my permission to look at my health records even if I withdraw from the 
trial. I agree to this access [ ]  
I understand that my identity will not be revealed in any information released to 
third parties or published [ ]   






Name of witness: 











ANNEXURE-2 MASTER CHART 
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SCORES  POST  GABA SCORES -- WEEKLY   POST GABA SCORES  --   FORTNIGHT 
         
REMARKS 







1 CHITRA 006629D 29 / F 07/10/2008 14 9 8 9 8 10 9 8 8 8 9 8 9 8 9 8 8 8 8 Trial given after 3 months. Total duration 9 months. 
2 BHARAT 323006D 12 / M 26/09/2008 14 9 9 8 10 8 7 9 8 8 8 9 9 8 8 7 8 7 8 Trial given after 3 months. Total duration of course 8 months 
3 DHARUN 422440 5 / M 10/03/2008 13 8 7 8 8 7 7 8 8 9 8 7 7 8 7 8 7 7 7 Trial given after 3 months. Total duration 9 months. 
4 GOMATHY 432440 18 / F 08/06/2008 14 9 8 7 7 7 7 8 7 7 8 8 7 7 7 8 7 7 7 Trial given after 3 months. Total duration 9 months. 
5 MOHAN.G 346721D 28 / M 17/09/2008 13 8 8 8 8 9 7 7 7 8 8 8 7 7 7 8 8 7 7 Trial given after 3 months. Total duration 9 months. 
6 PALANIYAPPAN 401752D 36 / M 12/10/2008 14 8 7 7 7 7 7 7 8 7 7 8 7 7 7 7 8 7 7 Trial given after 3 months. Total duration 9 months. 
7 LAKSHMI 198957D 23 / F 16/12/2008 12 10 9 8 9 9 8 9 9 9 8 8 9 9 9 8 9 9 9 Trial given for 3 months. Total duration 6 months. 
8 JAYABALAN 432456D 43 /M 14/10/2008 13 12                  Lost to follow up 
9 SARASWATHI 474292D 22 / F 12/06/2009 12 11 11 10 8 9 10 9 8 9 9 8 8 9 8 9 9 8 8 Trial given after 3 months. Still on therapy 
10 PUTUL TIWARI 542376d 36 /M 08/02/2009 14 12                  Lost to follow up 
11 JAYANTHI 160532D 30 / F 25/06/2008 14 9 8 8 9 10 9 8 7 8 8 9 9 8 8 8 9 8 9 Trial given after 3 months. Total duration 7 months. 
12 SARAVANAN 240849C 35 / M 10/05/2009 13 10 9 8 8 8 9 8 9 9 9 8 8 8 8 9 9 8 8 Trial given after 3 months. Total duration 6 months. 
13 SAKTHI 519689D 37 / M 11/06/2009 13 9 8 9 8 9 9 8 8 8 9 9 8 8 8 9 9 8 9 Trial given after 3 months. Total duration 7 months. 
14 JOSEPH 603732C 28 / M 10/02/2009 13 8 8 9 8 7 8 9 9 8 8 8 7 7 8 8 8 7 8 Trial given after 3 months. Total duration 8 months. 
15 VALARMATHI 401654D 39 / F 14/12/2008 12 9 9 8 8 9 9 9 8 9 8 8 9 9 8 8 9 9 9 Trial given after 3 months. Total duration 6 months. 
16 SANGEETHA 291202D 25 / F 16/08/2008 13 8 7 8 8 9 8 8 9 8 7 8 8 7 8 7 8 9 8 Trial given after 3 months. Total duration 9 months. 
17 SHANKAR 543245d 35 /M 12/08/2008 14 13                  Lost to follow up 
18 RAMESH 402578D 9 / M 12/01/2009 14 9 8 9 8 9 9 8 8 7 8 8 7 8 9 8 8 8 8 Trial given after 3 months ,total duration 5 months 
19 CHONG BALAMA 404087D 45 / M 10/11/2009 12 8 9 9 9 8 10 9 8 9 9 8 9 9 8 9 9 9 9 Trial given after 3 months. Total duration 9 months. 
20 RAHUL 260571D 9 / M 21/01/2009 14 9 8 9 8 8 7 7 8 7 8 8 9 8 8 7 8 8 7 Trial given after 3 months. Total duration 8 months. 
21 TANDRA DAS 584481D 27 / F 14/01/2009 14 8 8 7 9 8 7 7 7 8 7 8 7 8 7 7 8 7 7 Trial given after 3 months. Total duration 8 months. 
22 SWAPNA 512547D 29 / F 22/12/2008 15 9 8 7 7 8 7 8 7 7 7 8 7 7 8 7 7 7 7 Trial given after 3 months. Total duration 8 months. 
23 SANJAY GORAI 557197D 28 / M 20/02/2009 14 10 8 7 8 7 7 9 7 7 8 7 7 7 8 7 7 8 7 Trial given after 3 months. Total duration 8 months. 
 
